ClinicalTrials.gg
RecruitingNCT07472478GIVENUpdated Oct 23, 2026

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

A Phase 2 interventional study of Garsorasib and Ivonescimab Combined With Chemotherapy in Lung Cancer (NSCLC) and KRAS G12C Lung Cancer, sponsored by Guangdong Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Guangdong Provincial People's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 23, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital — 7 open to participants now, 7 under way, none of them phase 3. Lung Neoplasms · Guangdong Provincial People's Hospital.

Started
2026
the only one that year
Phase 2
Only one
of the 12
Registered
12th of 12
by date

Among the 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital, this one is the only one that started in 2026, is the only one in phase 2, and was the 12th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

7 of the 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lung Neoplasms by Guangdong Provincial People's Hospital, or all of them as a file.
02

Study summary

This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy as perioperative treatment for this patient population.

03

Conditions studied

  • Lung Cancer (NSCLC)
  • KRAS G12C Lung Cancer

Keywords

  • lung cancer
  • KRAS
  • KRAS G12C
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age Range: Males or females aged 18 years or older.
  2. Diagnosis and Stage: Patients with or cytologically confirmed resectable IB-IIIB NSCLC, staged according to the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology, 9th Edition.
  3. : Patients must voluntarily participate in the study, provide written informed consent, and be willing to comply with follow-up procedures.
  4. Prior Therapy: No prior systemic therapy for locally advanced or NSCLC (including chemo/radiotherapy, neoadjuvant chemo/radiotherapy, definitive chemoradiotherapy, chemotherapy, radiotherapy, , targeted therapy, or anti-angiogenic therapy for locally advanced disease).
  5. Mutation Status: KRAS G12C mutation positivity must be confirmed by next-generation sequencing (NGS) or polymerase chain reaction (PCR) testing.
  6. : At least one measurable target lesion as per v1.1. Lesions previously treated with radiotherapy or other local-regional therapies cannot be considered target lesions unless clear progression has been documented post-radiotherapy. At baseline, the lesion must be ≥10mm in the longest diameter (≥15mm in short axis for lymph nodes) on CT or MRI and be suitable for accurate repeated measurement per RECIST v1.1.
  7. Performance Status: (ECOG) performance status score of 0 or 1.
  8. Adequate Organ Function: Must meet the following criteria within 14 days prior to relevant tests, without transfusion or use of hematopoietic growth factors:

    1. (PLT) ≥90 × 10\^9/L
    2. (HGB) ≥90 g/L
    3. (ANC) ≥1.5 × 10\^9/L
    4. Serum creatinine ≤1.5 × or (CrCl) ≥50 mL/min (calculated using the Cockcroft-Gault formula)
    5. (ALT), Aspartate Aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if liver metastases are present)
    6. Total (TBIL) ≤1.5 × ULN (≤3 × ULN for patients with Gilbert's syndrome)
    7. (INR) or Prothrombin Time (PT) ≤1.5 × ULN, and Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN, or patients assessed by the investigator as having controlled bleeding tendency.
    8. Urinalysis showing urine protein \<2+ or 24-hour urinary protein quantification \<1g.
  9. : Expected survival time ≥3 months.
  10. : Fertile female subjects must agree to use effective contraception (e.g., IUD, oral contraceptives, condoms) during the study and for 6 months after study completion; have a negative serum pregnancy test within 7 days before enrollment; and must not be breastfeeding. Male subjects must agree to use effective contraception during the study and for 6 months after study completion.

Exclusion criteria

Exclusion Criteria:

  1. Prior Anti-Tumor Therapy:

    1. Previous receipt of any anti-tumor therapy for lung cancer (including adjuvant chemoradiotherapy, chemoradiotherapy, chemotherapy, radiotherapy, , targeted therapy, anti-angiogenic therapy, etc.).
    2. Treatment with any other drug within 28 days prior to the first dose in this study.
    3. Treatment within 2 weeks prior to the first dose with NMPA-approved Chinese patent medicines explicitly indicated for anti-tumor purposes in their drug说明书 (e.g., Compound Banmao Capsules, Kang'ai Injection, Kanglaite Capsules/Injection, Aidi Injection, Yadanzi Oil Injection/Capsules, Xiaoaiping Tablets/Injection, Huachansu Capsules, etc.).
  2. Recent Surgery: Any surgery within 4 weeks prior to screening examinations.
  3. Concurrent Primary : Patients with a concurrent primary malignancy (except for adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.).
  4. Abnormal Organ Function: Meeting any of the following at screening:

    1. (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times the (ULN).
    2. rate (CrCl) > ULN.
  5. Hematological Abnormalities: Total white blood cell (WBC) count > 10.0 × 10\^9/L or \< 1.0 × 10\^9/L at screening.
  6. Significant Comorbidities: History of immunodeficiency diseases (e.g., ), other active cancers or malignancy history, diseases, severe cardiovascular or cerebrovascular diseases, or any other diseases that may significantly reduce .
  7. Conditions Affecting Compliance: Any history of conditions that may affect protocol compliance (e.g., severe psychiatric disorders, cognitive dysfunction, drug abuse or addiction).
  8. Pregnancy, Lactation, and : Pregnant or lactating women, or subjects of unwilling or unable to use effective contraception.
  9. Allergy: Known allergy to any component of the study drug(s).
  10. Recent Trial Participation: Participation in any drug clinical trial within 6 months prior to screening.
  11. Investigator's Discretion: Any condition considered by the investigator as unsuitable for study participation.
  12. Other Driver Mutations: Non-small cell lung cancer with other standard-therapy-eligible driver gene mutations (e.g., EGFR, ALK, BRAF V600E, , MET Exon 14, ROS1, RET, or NTRK1/2/3).
  13. Central Nervous System (CNS) :

    1. Symptomatic or progressive or carcinomatous meningitis.
    2. Subjects with a history of brain metastases may be considered if they are clinically stable: no neurological symptoms, no treatment required, no indication for radiotherapy, and the largest diameter of the largest metastatic lesion on recent imaging is ≤ 1.5 cm.
    3. Asymptomatic CNS metastases newly discovered during screening are allowed.
    4. Subjects with a history of asymptomatic CNS metastases require confirmation of no progression via imaging scans performed at least 2 weeks apart.
    5. Subjects with symptomatic CNS metastases may be considered if clinically stable after radiotherapy and/or surgery.
    6. Subjects who underwent surgery for CNS metastases must have an interval of at least 4 weeks before the first study dose.
    7. Asymptomatic subjects after CNS radiotherapy must have discontinued corticosteroids for at least 2 weeks prior to the first dose.
  14. Cardiovascular Disease: Any of the following:

    1. Congestive heart failure of Class II or above.
    2. Severe arrhythmia requiring medication.
    3. Acute myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass graft within 6 months prior to enrollment.
    4. (LVEF) \< 50%.
    5. Prolonged interval ( > 470 ms for females, > 450 ms for males) or risk factors for Torsades de Pointes.
    6. Uncontrolled hypertension (systolic BP ≥ 150 mmHg and/or diastolic BP ≥ 100 mmHg after antihypertensive therapy).
  15. Thromboembolic Events: Arterial/venous thrombotic events within 6 months, hypertensive crisis, or hypertensive encephalopathy.
  16. History of Epilepsy: Previous history of epilepsy.
  17. Superior Vena Cava Syndrome: Presence of superior vena cava syndrome.
  18. Pulmonary Disease: Active non-infectious interstitial lung disease, radiation pneumonitis, etc., active tuberculosis, pneumoconiosis, ≥ Grade 2 other pneumonias, or severely impaired pulmonary function at screening.
  19. Severe Bone Lesions: Existing or potential severe bone damage from metastases, or uncontrolled bone pain.
  20. Active Infection: Active or uncontrolled severe infection, or unexplained fever > 38.5°C.
  21. Third-Space Fluid: Poorly controlled or drainage-requiring pleural effusion, ascites, or pericardial effusion. Subjects stabilized after treatment may be enrolled.
  22. Tumor Invading Major Vessels: Imaging shows tumor invading or with unclear boundaries to major blood vessels.
  23. Bleeding Risk: Evidence or history of bleeding tendency within 2 months before the first dose; history of hemoptysis, or unhealed wounds/ulcers/fractures within 2 weeks before the first dose.
  24. Gastrointestinal Diseases: Known GI impairment or diseases significantly affecting drug absorption/metabolism, or major GI surgery affecting absorption.
  25. Recent : Administration of a live attenuated vaccine within 4 weeks before the first dose.
  26. Severe to mAbs: History of severe hypersensitivity reaction to other monoclonal antibodies.
  27. Autoimmune Disease: Active autoimmune disease requiring systemic treatment within 2 years before the first dose.
  28. Therapy: Receiving systemic corticosteroids or other immunosuppressive therapy.
  29. Viral Infections: Positive HIV antibody, or active viral hepatitis.

    1. Active or active .
    2. Carriers require antiviral therapy and monitoring during the study.
  30. Active Syphilis.
  31. Renal Failure: Requiring hemodialysis or peritoneal dialysis.
  32. Poorly Controlled Diabetes: Fasting blood glucose > 10 mmol/L.
  33. Organ Transplant: History of or planned organ transplantation.
  34. Recent Major Surgery/Trauma: Major surgery or significant trauma within 4 weeks before the first dose.
  35. Recent Radiotherapy: Palliative radiotherapy within 2 weeks before the first dose.
  36. Residual Toxicity from Prior Therapy: Toxicities from previous anti-cancer therapy not recovered to Grade ≤1.
  37. Other: Any other abnormality or disease deemed by the investigator to pose risk or interfere with the study.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant therapy phase

    sequential preoperative regimen beginning with a 4- to 6-week lead-in phase of targeted monotherapy using Garsorasib (600 mg twice daily), followed by three cycles of combination chemoimmunotherapy comprising Ivonescimab (20 mg/kg), pemetrexed, and carboplatin, ultimately culminating in definitive surgical resection.

    Drug: Garsorasib · Drug: Ivonescimab Combined With Chemotherapy · Procedure: Surgery · Drug: Ivonescimab · Behavioral: Observation

Interventions

  • Garsorasib 600 mg, twice daily, for 4 to 6 weeks

  • DrugIvonescimab Combined With Chemotherapy

    Drug page: IvonescimabStudies of IvonescimabIvonescimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After a 2-week washout period, administer Ivonescimab 20 mg/kg in combination with the PC regimen (paclitaxel 135-175 mg/m² + carboplatin AUC 5) every 3 weeks.

  • ProcedureSurgery

    Surgery

  • If MRD is positive and KRAS is positive, adjuvant therapy with Garsorasib 600 mg twice daily should be administered until disease progression, unacceptable toxicity, withdrawal of informed consent, death, or termination due to other reasons, whichever occurs first.

  • If MRD is positive and KRAS is negative, adjuvant therapy with Ivonescimab 20 mg/kg every 3 weeks should be administered until disease progression, unacceptable toxicity, withdrawal of informed consent, death, or termination due to other reasons, whichever occurs first.

  • BehavioralObservation

    If MRD is negative, the patient should be placed under observation; once it turns positive, they will enter the corresponding treatment group as described above.

06

What researchers measure

Primary outcomes

  1. Pathologic complete response (pCR) rate assessed according to the IASLC recommendations for pathologic evaluation of lung cancer neoadjuvant therapy

    Time frame: 14-24 weeks

Secondary outcomes

  1. Major Pathological Response (MPR) rate assessed according to the IASLC recommendations for pathologic evaluation of lung cancer neoadjuvant therapy

    Time frame: 14-24 weeks

  2. R0 resection rate

    Time frame: 24 months

  3. Objective Response Rate (ORR)

    Time frame: From initiation of neoadjuvant therapy until the final preoperative imaging assessment, up to 24 weeks (each cycle is 3 weeks).

  4. One-year event-free survival rate (1-y EFS%)

    Time frame: 12 months

  5. Event-Free Survival (EFS)

    Time frame: From the date of first dose until the end of event-free status (disease progression, recurrence, or death from any cause), assessed up to 60 months.

  6. Overall Survival

    OS was defined as the time from the start of treatment to the date of death.

    Time frame: 60 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 285 non-industry phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 113. This study's planned 21 months is below that.

Counting every sponsor, half of 362 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 16, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added — first site in China
Show site
  • Guangdong Provincial People's Hospital · Guangzhou, China
Oct 23, 2026
Start date
Mar 15, 2026→Mar 20, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Guangdong Provincial People's Hospital · Guangzhou, China
    Start date Mar 15, 2026→Mar 20, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07472478
Responsible party
Wen-zhao ZHONG (Principal Investigator, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Mar 16, 2026
Start date
Mar 20, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Wen-Zhao Zhong, MD
Contact
13609777314@163.com
86-13609777314

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Garsorasib · Ivonescimab

Start the discussion